ZIM
BEAT

Zacks Investment Management’s BioTelemetry, Inc. BEAT Stock Holding History

Zacks Investment Management’s Portfolio BEAT Stock Details BEAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,392
Closed -$277K – 692
2017
Q3 		$277K Hold
8,392
– – 0.01% 479
2017
Q2 		$281K Sell
8,392
-5,552
-40% -$166K 0.01% 496
2017
Q1 		$404K Buy
13,944
+3,908
+39% +$96.8K 0.01% 474
2016
Q4 		$224K Buy
+10,036
New +$196K 0.01% 575
2015
Q2 		– Sell
-16,087
Closed -$142K – 792
2015
Q1 		$142K Buy
+16,087
New +$163K ﹤0.01% 610
2014
Q3 		– Sell
-34,719
Closed -$249K – 839
2014
Q2 		$249K Buy
+34,719
New +$276K 0.01% 619

Other funds holding BEAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Zacks Investment Management's BEAT Position: Q4 2017 in Review

Zacks Investment Management sold out of BioTelemetry, Inc. (BEAT) in Q4 2017, closing a stake of 8,392 shares — an estimated $277K sold.

Zacks Investment Management first reported a position in BEAT in Q2 2014 and held it in 6 quarters. The position peaked at $404K in Q1 2017. 192 funds tracked by Wall St. Rank hold BEAT as of Q4 2017.

  • Zacks Investment Management reported no remaining BioTelemetry, Inc. position as of Q4 2017 after selling out during the quarter.
  • Zacks Investment Management sold 8,392 BioTelemetry, Inc. shares in Q4 2017, an estimated $277K.
  • Zacks Investment Management first reported a position in BioTelemetry, Inc. in Q2 2014 and held it in 6 quarters.
  • Zacks Investment Management's BioTelemetry, Inc. position peaked at $404K in Q1 2017.
  • 192 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q4 2017.

Based on Zacks Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.